Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbogen is a medical gas mixture composed of 95–98% oxygen and 2–5% carbon dioxide. It is used as an inhalant to increase tissue oxygenation and cerebral blood flow by raising blood carbon dioxide levels, which leads to vasodilation. Carbogen has been investigated for its radiosensitizing properties in cancer therapy, particularly as an adjunct to radiotherapy, and for acute treatment in conditions such as sudden sensorineural hearing loss (where a vascular cause is suspected), seizures in epilepsy patients, central retinal artery occlusion, stroke, and other indications. Its effectiveness remains unproven or experimental for most uses[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbogen.